Cuprina Appoints Dr. Ronald Sherman, Leader in Maggot Debridement Therapy, as Medical and Scientific Director; Secures FDA-approved Medical Maggot License for U.S. Market

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that Dr. Ronald A. Sherman, a leading innovator in the use of medical maggots to treat chronic wounds, has agreed to join the Company as Medical and Scientific Director in September 2025.

Read more at globenewswire.com